Market Size and Growth Forecast

The global market for palmoplantar pustulosis, encompassing the major markets of North America, Europe, Asia-Pacific, the Middle East, and Africa, and South America, has shown significant growth, reaching a value of approximately US$ 532.0 Million in 2023. Analysts from the DISEASE ROOT ANALYSIS Group project that this market is poised to expand further, with an anticipated growth to US$ 1,064.5 Million by 2032. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of 6.51% during the forecast period from 2024 to 2032. This bullish outlook is explored in depth in DISEASE ROOT ANALYSIS's latest report titled "Palmoplantar Pustulosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032."

The expansion of the palmoplantar pustulosis market is influenced by several factors, including increased awareness of the condition, better diagnostic methods, and improved healthcare infrastructure across various regions. Additionally, global healthcare shifts towards personalized medicine and more effective disease management strategies are anticipated to offer new opportunities for market growth. These developments are expected to lead to earlier diagnosis and more effective treatment regimens, which in turn can improve outcomes for patients suffering from this painful and debilitating condition.

Furthermore, demographic changes such as aging populations in developed countries and increasing lifespans worldwide contribute to the market's expansion. As the global population ages, the prevalence of chronic diseases, including skin disorders such as palmoplantar pustulosis, is expected to rise, thereby driving demand for effective treatment solutions. The market's growth is also supported by ongoing clinical trials and research aimed at understanding the pathophysiology of the disease, which is likely to result in the development of novel therapeutic options and enhance the existing treatment landscape.

1. Key Insights

2. Report Introduction

3. PPP Market Overview at a Glance

3.1. Market Share (%) Distribution of PPP by Country in 2023 in the 7MM

3.2. Market Share (%) Distribution of PPP by Country in 2032 in the 7MM

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1. Palmoplantar Pustulosis (PPP)

7.2. Clinical Presentation and Severity Assessment

7.3. Histology

7.4. Risk Factors

7.4.1. Smoking

7.4.2. Infections and Stress

7.4.3. Metal Allergy

7.4.4. Triggering Drugs

7.4.5. Concomitant Diseases

7.5. Quality of Life and Psychiatric Disorders

7.5.1. Genetic Background

7.6. Pathogenesis

7.7. Differentiating Palmoplantar Pustulosis from Palmoplantar Pustular Psoriasis (PPPP)

8. Treatment and Management of PPP

8.1. Topical Treatment

8.2. Phototherapy

8.3. Systemic Treatment

8.4. Targeted Therapies Approved for Psoriasis Vulgaris

8.4.1. TNF Inhibitors

8.4.2. IL-12/23 Inhibitors

8.4.3. IL-23 Inhibitors

8.4.4. Phosphodiesterase-4 (PDE-4) Inhibitor

8.5. Emerging Agents

8.5.1. IL 8 Inhibitors

8.5.2. IL-36 Inhibitors

8.5.3. IL-1 Inhibitors

8.5.4. Granulocyte Colony Stimulating Factor Receptor Inhibitor

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale

9.3. Total Diagnosed Prevalent Cases of PPP in 7MM

9.4. Total Treated Cases of PPP in 7MM

9.5. The United States

9.5.1. Total Diagnosed Prevalent Cases of PPP in the United States

9.5.2. Gender-specific Cases of PPP in the United States

9.5.3. Age group-specific Cases of PPP in the United States

9.5.4. Severity-specific Cases of PPP in the United States

9.5.5. Treated Cases of PPP in the United States

9.6. EU4 and the UK

9.6.1. Total Diagnosed Prevalent Cases of PPP in EU4 and the UK

9.6.2. Gender-specific Cases of PPP in EU4 and the UK

9.6.3. Age group-specific Cases of PPP in EU4 and the UK

9.6.4. Severity-specific Cases of PPP in EU4 and the UK

9.6.5. Total Treated Cases of PPP in EU4 and the UK

9.7. Japan

9.7.1. Total Diagnosed Prevalent Cases of PPP Japan

9.7.2. Gender-specific Cases of PPP in Japan

9.7.3. Age group-specific Cases of PPP in Japan

9.7.4. Severity-specific Cases of PPP in Japan

9.7.5. Treated Cases of PPP in Japan

10. Patient Journey

11. Marketed Therapies

11.1. Key Cross Competition

11.2. TREMFYA (Guselkumab): Janssen Pharmaceuticals/Taiho Pharmaceutical

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Clinical Development

11.2.5. Safety and Efficacy

11.3. LUMICEF (Brodalumab): Kyowa Kirin

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Other Developmental Activities

11.3.4. Clinical Development

11.3.5. Safety and Efficacy

11.4. SKYRIZI (Risankizumab): AbbVie/Boehringer Ingelheim

11.4.1. Product Description

11.4.2. Regulatory Milestones

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

12. Emerging Therapies

12.1. Key Cross Competition

12.2. OTEZLA (apremilast): Amgen

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Developmental Activities

12.2.4. Safety and Efficacy

12.2.5. Analyst View

13. Palmoplantar Pustulosis (PPP): 7 Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Conjoint Analysis

13.4. Key Market Forecast Assumptions

13.5. Total Market Size of PPP in the 7MM

13.6. United States Market Size

13.6.1. Total Market Size of PPP in the US

13.6.2. Market Size of PPP by Therapies in the US

13.7. EU4 and the UK Market Size

13.7.1. Total Market Size of PPP in EU4 and the UK

13.7.2. Market Size of PPP by Therapies in EU4 and the UK

13.8. Japan Market Size

13.8.1. Total Market Size of PPP in Japan

13.8.2. Market Size of PPP by Therapies

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer